ASCO 2026: AI Challenges a Breast Cancer Standard - Summary - MDSpire
Advertisement
ASCO 2026: AI Challenges a Breast Cancer Standard
New data suggest AI-based analysis of pathology slides may provide additional prognostic information, particularly for patients in the intermediate-risk category
To compare the prognostic performance of a multimodal artificial intelligence histopathology-based tool (Artera) versus the 21-gene recurrence score in early-stage breast cancer.
Key Findings:
Patients with a recurrence score of 0-10 showed 84% concordance with Artera low scores.
Patients with concordantly low scores had no recurrences at 10 years, while those with discordant scores (Oncotype low, Artera high) had a 20% 10-year distant metastasis rate.
In the intermediate risk category (11-25), a third of patients had discordant scores, with significant differences in 10-year distant metastasis rates.
Interpretation:
The Artera AI test provides additional prognostic value beyond the 21-gene recurrence score in early-stage breast cancer.
Limitations:
Conclusion:
The MMAI score demonstrates prognostic risk stratification in a contemporary treated patient population.
